Vaccine against RSV
Compositions including a recombinant respiratory syncitial virus (RSV) Fusion (F) polypeptide that is stabilized in the pre-fusion conformation are described. The RSV F polypeptide includes at least one mutation as compared to a wild type RSV F polypeptide and the at least one mutation is a) a mutation of the amino acid aspartic acid (D) on position 486, b) a mutation of the amino acid aspartic acid (D) on position 489, or c) a mutation of the amino acid serine (S) on position 398 and/or the amino acid lysine (K) on position 394. Compositions including an isolated nucleic acid molecule encoding the stable RSV F polypeptides are also described.
1. An adenovirus type 26 (Ad26) vector comprising a nucleic acid molecule encoding a recombinant respiratory syncytial virus (RSV) Fusion (F) polypeptide, wherein, as compared to a wild type RSV F polypeptide, the recombinant RSV F polypeptide comprises:
(i) a mutation of the amino acid at position 486 from aspartic acid (D) to asparagine (N), and
(ii) at least one of
a. a mutation of the amino acid residue at position 67 from asparagine (N) or threonine (T) to isoleucine (I), and
b. a mutation of the amino acid residue at position 215 from serine (S) to proline (P).
2. The vector according to claim 1 , wherein the RSV F polypeptide comprises:
(i) the mutation of the amino acid at position 486 from aspartic acid (D) to asparagine (N),
(ii) the mutation of the amino acid residue at position 67 from asparagine (N) or threonine (T) to isoleucine (I), and
(iii) the mutation of the amino acid residue at position 215 from serine (S) to proline (P).
3. A composition comprising the vector according to claim 1 .
4. A method of inducing an immune response against RSV F protein in a subject in need thereof, the method comprising administering to the subject the vector according to claim 1 .
5. A pharmaceutical composition comprising the vector according to claim 1 , and a pharmaceutical carrier.
6. A composition comprising the vector according to claim 2 .
7. A method of inducing an immune response against RSV F protein in a subject in need thereof, the method comprising administering to the subject the vector according to claim 2 .
8. A pharmaceutical composition comprising the vector according to claim 2 , and a pharmaceutical carrier.